Details of the Drug
General Information of Drug (ID: DM1MRFW)
Drug Name |
NSC-119911
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
NSC119911; CHEMBL258670; CHEMBL3260988; NSC-119911; MLS-0111616.0001; AC1OBGP2; AC1NTI1U; AC1NS1JN; SCHEMBL2846330; SCHEMBL2846323; CHEMBL502775; (9Z)-9-(3,3-dihydroxyprop-2-enylidene)-5,6-dihydroxyxanthene-3,4-dione; ZINC3954334; BDBM50011357; NSC158917; NCI119911; CCG-36604; BDBM50373125; NSC-158917; 9-(3,3-dihydroxyprop-2-enylidene)-5,6-dihydroxyxanthene-3,4-dione; (E)-3-(3,4,5-trihydroxy-6-oxo-xanthen-9-yl)prop-2-enoic acid; 2-Propenoic acid, 3-(4,5,6-trihydroxy-3-oxo-3H-xanthen-9-yl)-, (2E)-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 314.25 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 0.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 4 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 7 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||